Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev® versus placebo
- Category: Small Molecules
- Published on Friday, 10 November 2017 16:59
- Hits: 746
- Patients treated with Ofev® had less progression of lung fibrosis at six months vs. those treated with placebo in Phase IIIb exploratory analysis
- First data to suggest that Ofev® slowed fibrotic process as measured by high-resolution CT imaging
RIDGEFIELD, CT, USA I November 10, 2017 I Boehringer Ingelheim today announced results from a descriptive Phase IIIb lung imaging study providing evidence for the first time that Ofev® (nintedanib) slowed the fibrotic process versus placebo in people with idiopathic pulmonary fibrosis (IPF). The results are being presented at the Pulmonary Fibrosis Foundation (PFF) Summit 2017, November 9-11 in Nashville, Tenn.
The study showed a reduction in the development of lung fibrosis among people treated with Ofev, as measured by quantitative lung fibrosis score (QLF), which uses high resolution CT (HRCT) imaging to measure the extent of lung fibrosis (thickening and scarring of the lungs). Lower QLF scores indicate less fibrotic progression in the lung. In this study, the QLF score from baseline to 6 months was 11.4% in people treated with Ofev versus 14.6% in the placebo group (difference 3.2%, exploratory endpoint not statistically significant).
"With the aid of high resolution CT scans, we have observed a reduction in the progression of lung fibrosis with Ofev versus placebo," said lead study investigator Lisa Lancaster, M.D., clinical director of the Interstitial Lung Disease Program at Vanderbilt University Medical Center. "These encouraging results demonstrate that through an imaging scan we identified differential responses in fibrotic changes between groups that will help doctors make informed treatment decisions."
The primary endpoint of this randomized, double-blind, placebo-controlled, descriptive trial was change in relative QLF score from baseline to 6 months of treatment.
A secondary endpoint of the trial was absolute mean change in forced vital capacity (FVC), a measure of lung function. At baseline, mean FVC was 2997 (831) mL among people treated with Ofev and 2921 (834) mL among people on placebo. The adjusted mean absolute changes in FVC from baseline to month 6 were −14.2 mL and −83.2 mL in the Ofev and placebo groups, respectively (difference 69.0 mL).
"This study reaffirms the beneficial effect of Ofev for reducing lung function decline and slowing disease progression, and is the first to suggest that there may be a differential effect of Ofev treatment versus placebo in lung fibrosis change," said Thomas Leonard, Ph.D., executive director, Clinical Development and Medical Affairs, Specialty Care, Boehringer Ingelheim. "We look forward to presenting additional findings from this study at major medical congresses next year and confirmation of these results in future studies."
About idiopathic pulmonary fibrosis (IPF)
IPF is a rare and serious lung disease that causes permanent scarring of the lungs. It affects as many as 132,000 Americans, typically men over the age of 65. Early diagnosis and proper care are critical to helping people treat their condition.
About Ofev® (nintedanib)
The U.S. Food and Drug Administration (FDA) approved Ofev for the treatment of idiopathic pulmonary fibrosis (IPF) on October 15, 2014. Ofev is one of the first FDA-approved drug treatments for IPF and the only kinase inhibitor approved to treat this disease.
The approval was based on findings from a robust clinical trial program involving more than 1,200 patients with IPF worldwide, and included the Phase II TOMORROW™ trial and the Phase III INPULSIS® trials (INPULSIS®-1 and INPULSIS®-2). All these studies were randomized, double-blind, placebo-controlled trials comparing Ofev 150 mg twice daily to placebo for 52 weeks. Both INPULSIS® trials were identically designed while the TOMORROW™ study design was similar.
What is Ofev?
Ofev is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF). It is not known if Ofev is safe and effective in children.
About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world's top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
SOURCE: Boehringer Ingelheim